Healthcare challenges such as increasing consolidation, rising costs, reimbursement cuts and staff shortages are having a direct impact on labs. At the same time, molecular labs want to enhance their operational productivity to further solidify their positions as trusted healthcare partners.
Lab schedule efficiencies are often impacted by batch instrument limitations (need for batching and sorting samples).
Four to six platforms are often needed for routine PCR testing, causing inefficiencies and requiring more staff training and broader knowledge.
Highly skilled staff spend hours each day on tedious tasks.
Data is not easily or effectively used to optimize performance.
Alinity m is a fully integrated and automated molecular diagnostics analyzer that uses innovative technology to deliver the next level of flexibility and efficiency to your lab.
We surveyed health systems and labs around the world to develop the Alinity m to meet your needs, now and into the future.SPECIFICATIONS
Providing true random access and STAT prioritization
Ability to manage the majority of routine PCR tests on a single platform
Driving standardization through simple, universal design elements
Delivering on the Abbott legacy of high-quality product designs and assays
ReadiFlex enables you to achieve true random access by balancing flexibility, turnaround time, and throughput.
Perform any test, any time, including STAT samples
Rapid turnaround time for all assays
Consistent throughput regardless of assay mix
Abbott Diagnostics has been on the forefront of innovation for more than 30 years. Alinity m benefits from this legacy and commitment to high quality assay development.
- Innovative technology underpinned by robust design to provide accurate, consistent results
- ReadiFlex (random access) technology enables you to improve your workflow and increase productivity
- Alinity m SARS-CoV-2 assay is authorized by the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) only for COVID-19 testing
- Alinity m HCV and HIV assays are approved by the FDA
- The future pipeline menu including HBV* and STI**Alinity m HBV and STI assays are in development and are not commercially available in the US
Reduces complexity and streamlines workflow
Improve resource flexibility and ease of training
Drives maintenance and service cost optimization
Have an Abbott Molecular Laboratory representative contact you about our lab solutions.
Receive exclusive access to resources with the Abbott Customer Portal (Diagnostics Portal).
Representatives are ready to offer support, gather feedback, and answer questions.
Surging ahead. Staying informed.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.